Business Weekly East of England - Latest stories

Region underwhelmed by the internet

News Desk — Fri, 06 Nov 2009 17:27:07 +0000

New research from PR agency, Golley Slater suggests that despite the East of England's status as one of Europe's leading innovation clusters, large parts of the population in this region are still unconvinced about the merits of the digital revolution.

Developers blasted for biotech myopia

Tony Quested — Thu, 05 Nov 2009 16:00:04 +0000

One of Cambridge's most exciting biotech companies is ramping up its local operations with a move to a new UK headquarters in the region in late November but has blasted the poor property provision for companies in Europe's fastest growing biotech sector.

IfM to help make Australia a world leader in green vehicles

News Desk — Thu, 05 Nov 2009 15:56:14 +0000

The Australian government has turned to Cambridge University to help plan the long term future of the country's automotive industry.

Darrin M Disley, chairman of Horizon Discovery

Tony Quested — Thu, 05 Nov 2009 12:04:09 +0000

About Horizon Discovery: Horizon Discovery is a translational genomics company headquartered in Cambridge with an additional R & D site in Turin. The company employs a proprietary gene-manipulation technique to develop a range of (150) genetically-defined, invitro, human cancer cell models that enable the development of drugs, diagnostics & theranostics targeted against a patient's genetic make-up.
The company's intellectual property, knowhow and product-lines promise to enable the field of personalised medicine to take a step nearer its goal of administering the right drug to the right patient at the right time.

Norfolk breakthrough could aid food security

News Desk — Thu, 05 Nov 2009 11:09:40 +0000

Norfolk scientists have made a discovery that they hope could improve food security in the future.

blinkx seeks £5m

News Desk — Thu, 05 Nov 2009 10:49:06 +0000

blinkx plc, the video search specialist spun out of Autonomy, is to increase its share capital by 10 per cent as it seeks to raise £5 million through a shares placing.

NXT technology used in bus system

News Desk — Thu, 05 Nov 2009 09:42:24 +0000

Flat panel speaker pioneer, NXT, has confirmed its SurfaceSound technology has been installed in the Intelligent Bus Information System currently being trialled at local authorities across the UK and set for a wider roll out in 2010.

Designed by ACIS, the Intelligent Bus Information System (IBIS) is a pole-mounted interactive display designed to allow the public to plan travel routes using existing transportation facilities by offering upto-date scheduled and real-time travel information for urban and rural locations.

IBIS also provides walking and cycling routes, news feeds, weather bulletins, public notices and advertisements, while the touch screen display carries an in-built NXT audio system for the text-to-speech function.

Axon previews electric car in Milton Keynes

News Desk — Wed, 04 Nov 2009 16:06:33 +0000

Cleantech car developer, Axon Automotive, based in Northants, has previewed its plug-in hybrid electric vehicle at the Milton Keynes Science Festival.

Cyclacel makes progress with leukemia drug

News Desk — Wed, 04 Nov 2009 15:47:07 +0000

Cyclacel Pharmaceuticals said sapacitabine, its treatment for acute myeloid leukemia in elderly patients, has shown a 30 per cent survival rate in Phase II clinical trials, significantly outperforming rival therapies.

The data will be welcome news at the global biopharmaceutical company, which has had to stop looking for new targets and concentrate on its existing product pipeline, particularly sapacitabine. Cyclacel has greatly reduced its Cambridge base and ended research activities there, though the company cofounder and chief scientist, Professor David Glover, continues to operate out of its Babraham-based facility, which still supplies products for clinical trials.

Sapacitabine is targeted at people aged 70 or older with either newly diagnosed acute myeloid leukemia (AML) or AML in first relapse.

Cyclacel is now working with the Food and Drug Administration (FDA) in the US to design a Phase III study for its use in hematological malignancies - the cancer type that affects blood, bone marrow, and lymph nodes.

Women hold sway on house move decisions

News Desk — Wed, 04 Nov 2009 15:44:32 +0000

Women have a much greater say than men on whether to move house or not according to new research from the Institute for Social and Economic Research (ISER) at the University of Essex.